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therapy, and various mental disorders were combined with
these results to create a model that is almost 80 percent accu-
rate. Mortality can be predicted using the variables vascular
catheterization, respiratory intubation, and coronary athero-
sclerosis with an accuracy of 63.4 percent. CONCLUSION: A
bimodal trend in the age of drug abusers suggests two different
types of drug abuse. The most likely explanation is the abuse of
recreational drugs around the age of 40 and the abuse or
misuse of prescription drugs around the age of 80. Mortality
can be predicted so accurately using only three variables
because these procedures are associated with the highest prob-
ability of death.
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OBJECTIVE: The purpose of this study was to evaluate the
relative efﬁcacy of different atypical antipsychotic medications
(AAPs) in the treatment of schizophrenia using a Bayesian mixed
treatment comparison (MTC) model. METHODS: The Cochran
central register of controlled trials and PubMed database were
searched to identify randomized controlled clinical trials assess-
ing the efﬁcacy of AAPs (olanzapine, risperidone, clozapine,
aripiprazole, quetiapine, ziprasidone) in the treatment of schizo-
phrenia. Studies were included if they used change in the Positive
and Negative Syndrome Scale (PANSS) as an outcome measure.
Findings from these studies were analyzed using Bayesian meta-
analysis of direct and indirect comparisons. Both, ﬁxed and
random effects models were employed in the analysis. RESULTS:
Twenty eight trials were identiﬁed, which included a total of
6023 patients. The ﬁxed effects model indicated that clozapine
and olanzapine had signiﬁcantly greater improvements on the
PANSS overall scale (median change from baseline: 19.4 (95%
credible interval [CrI] 19.2–19.5) and 19.3 (95% [CrI] 19.3–
19.4) for clozapine and olanzapine respectively) than all other
AAPs. In the rank order analysis, clozapine had a 82% probabil-
ity of being the best treatment. Clozapine showed signiﬁcantly
more improvements on the positive subscale (mean change from
baseline 5.4 (95% [CrI] 5.2–5.5), and 100% probability of being
the best treatment). On the negative subscale, clozapine and
olanzapine showed signiﬁcantly more improvements than other
APPs. However, the random effects model found no signiﬁcant
differences among the AAPs in the magnitude of improvements
on the PANSS overall scale, as well as the positive and negative
subscales. This may be due to substantial inter-study variation.
CONCLUSION: Using a ﬁxed effects model, clozapine and olan-
zapine were found to be signiﬁcantly more efﬁcacious, but these
ﬁndings were not supported by the random effects analysis. More
direct comparisons are needed to make deﬁnitive conclusions
about the relative efﬁcacy of these agents.
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OBJECTIVE: One way to evaluate effectiveness of antipsychot-
ics is to measure frequency of symptomatic relapses in patients
with schizophrenia. The occurrence and duration of hospital-
izations are important markers of potential relapses. This study
assessed differences in days hospitalized among schizophrenic
patients receiving paliperidone extended-release tablets (pali-
peridone ER) during the 52-week open-label extension (OLE)
phases of three double-blind (DB) trials as compared to treat-
ment as usual (TAU) in the six months following the OLE
phases of these trials. METHODS: Data on resource use was
collected through retrospective chart review. Average number of
hospital days during OLE and TAU phases was calculated
including the use of bootstrap resampling methods to assess
statistical signiﬁcance of differences. Total person years were
calculated for OLE and TAU phases to account for different
lengths of observation. Antipsychotic use during TAU phase was
also evaluated. Paliperidone ER was not commercially available
during TAU phase. RESULTS: In this analysis, patients (n = 71)
were from the US (31.0%), Canada (21.1%) and Malaysia
(47.9%). Mean (SD) patient age was 37.9 (10.5) years; and
the majority were male (70.4%). During the OLE, the mean
paliperidone ER treatment duration (SD) was 212.9 (141.2)
days, and the mean dose was 11.4 (2.1) mg. Patients experi-
enced an average of 5.0 and 15.3 hospital days per person year
in OLE and TAU phases, respectively, indicating that a mean
increase of 10.3 days of hospitalization was observed during
TAU phase (95%CI 2.3,19.2, P = 0.006). During TAU phase,
the treatments received were second-generation antipsychotics
(SGAs) (52.1%), ﬁrst-generation antipsychotics (FGAs) (9.9%),
or both FGAs and SGAs (14.1%). CONCLUSION: Patients
discontinuing paliperidone ER after the OLE phases experi-
enced more hospital days compared to the OLE phases where
they received paliperidone ER. Whether this increase in hospital
days is associated with a greater frequency or severity of
relapses remains to be tested.
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OBJECTIVE: This study used signal detection methods to iden-
tify the optimal magnitude of early non-response to antipsychotic
medication at various early time points that best predicts subse-
quent non-response at eight weeks, using different criteria of
subsequent non-response. This analysis was implemented sepa-
rately for schizophrenia patients with at least moderate sym-
ptom severity, and for patients with lesser symptom severity.
METHODS: Data were pooled from ﬁve randomized, double-
blind clinical trials of atypical antipsychotics in the treatment of
patients with schizophrenia, schizoaffective disorder, or schizo-
phreniform disorder, and included 1437 patients (n = 1137 with
at least moderate symptom severity; n = 300 with lesser symptom
severity). Signal detection methods were used to identify the
optimal response threshold based on improvement from baseline
on the Positive and Negative Syndrome Scale (PANSS) total score
at different early time points (Week 1 to Week 4 of treatment) to
predict subsequent non-response at eight weeks, while control-
ling the false positive rate at 30% or less. RESULTS: The optimal
thresholds for patients with at least moderate symptom severity
were 7–12% at Week 1, 14–23% at Week 2, 20–38% at Week 3,
and 26–45% at Week 4. For patients with lesser symptom sever-
ity, the optimal thresholds were 3–4% at Week 1, 7–12% at
Week 2, 6–14% at Week 3, and 15–20% at Week 4. Results were
validated using data from another clinical trial. CONCLUSION:
Different early response thresholds appear to maximize identiﬁ-
cation of subsequent non-responders to antipsychotic medica-
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tions, reﬂecting differences in early time points and in illness
severity levels. For schizophrenia patients with at least moderate
symptom severity, the lack of at least 14–23% improvement on
the PANSS total score at two weeks is an optimal predictor of
subsequent non-response following eight weeks of treatment.
This early response threshold appears to be an important clinical
marker of subsequent non-response to antipsychotic therapy.
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OBJECTIVE: To evaluate the 12-month clinical and functional
outcomes in patients with schizophrenia who received RLAI
treatment and were enrolled in the electronic-Schizophrenia
Treatment Adherence Registry (e-STAR) in Australia and
Belgium, and the Schizophrenia Outcomes Utilization, Relapse,
and Clinical Evaluation (SOURCE) in the United States.
METHODS: e-Star and SOURCE are long-term, prospective,
observational studies of patients with schizophrenia who com-
mence RLAI treatment. Data are collected both retrospectively
and prospectively and clinical effectiveness was measured by the
Clinical Global Impression Severity (CGI-S) scale and patient
functioning was measured by the Global Assessment of Function-
ing (GAF) scale. RESULTS: Seven hundred sixty-nine patients
(Australia = 493, Belgium = 163, USA = 113) with 12-months
of follow-up data were included. Australia had signiﬁcantly
younger patients than Belgium and the United States (mean ages:
Australia = 38.6, Belgium = 41.6, USA = 43.5; p = 0.0003). Time
since diagnosis (in years) was signiﬁcantly higher in the United
States than Australia and Belgium (USA = 17.6, Australia = 11.6,
Belgium = 9.8; p < 0.0001). United Stats patients had signiﬁ-
cantly higher baseline GAF scores than the Australian and
Belgian patients (USA = 50.9, Australia = 42.7, Belgium = 43.1;
p < 0.0001). Despite baseline differences, GAF and CGI-S scores
at 12-months for patients treated with RLAI signiﬁcantly
improved from baseline in all three countries. CGI-S scores sig-
niﬁcantly decreased by 0.8 (p < 0.001), 1.08 (p < 0.001) and
0.83 (p < 0.001) points and GAF scores signiﬁcantly increased by
12.7 (p < 0.001), 14.8 (p < 0.001), and 11.1 (p < 0.001) points in
Australia, Belgium, and the United States respectively. CON-
CLUSION: This interim analysis from the two observational
studies shows that despite differences in patient characteristics
among countries, treatment with RLAI resulted in signiﬁcant
improvements in disease severity and patient functioning in
patients with schizophrenia from all three countries.
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OBJECTIVE: To assess differences in treatment duration and
resource utilization following initiation on atypical antipsychot-
ics among schizophrenia patients with versus without metabolic
syndrome who were treated at the Veteran Health Administra-
tion. METHODS: We used electronic medical records data for
October 2002-August 2005 from a large Veterans Integrated
Service Network (VISN16) to identify schizophrenia patients
who were initiated on an atypical antipsychotic and have under-
gone metabolic monitoring in the 180 days prior to medication
initiation. Those found to have a metabolic syndrome (MetSyn+)
were compared to those without (MetSyn-) on patient charac-
teristics, treatment duration, medication adherence per medica-
tion possession ratio (MPR), and resource utilization in the
1-year post medication initiation. Kaplan-Meyer (K-M) estima-
tion compared the difference in treatment duration. A Cox pro-
portional hazard regression was used to compare all-cause
medication discontinuation, controlling for group differences at
baseline. RESULTS: A minority of schizophrenia patients who
have undergone metabolic monitoring was found to have a meta-
bolic syndrome (83 of 593, or 14.0%). The MetSyn+ and
MetSyn- groups did not signiﬁcantly differ on baseline charac-
teristics except that the MetSyn+ group had a higher rate of
non-VA insurance. Adherence (MPR) during the year following
medication initiation was higher for the MetSyn+ group (81% vs.
68%; p = 0.031). K-M estimators (log-rank test p = 0.471; Wil-
coxon test p = 0.512) and a Cox model (p = 0.671) indicated
lack of statistically signiﬁcant group difference in all-cause medi-
cation discontinuation. CONCLUSION: Among schizophrenia
patients who have undergone metabolic monitoring, those with a
metabolic syndrome and those without do not appear to differ on
treatment duration and resource utilization following initiation
on an atypical antipsychotic medication in the Veterans Health
Administration.
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OBJECTIVE: Continuous treatment is an important goal in the
management of schizophrenia. Retention rate is a well-recognized
global measure of effectiveness that integrates patients’ and clini-
cians’ judgment of efﬁcacy, safety and tolerability. Furthermore,
all-cause discontinuation was used as a primary outcomemeasure
in a large effectiveness study (Clinical Antipsychotic trial of Inter-
vention Effectiveness or CATIE). The current study utilized lon-
gitudinal claims data fromOntario Drug Beneﬁt (ODB) recipients
in Ontario, Canada to compare retention rates for typical and
atypical antipsychotic medications with different formulations.
METHODS: Longitudinal data were obtained for ODB recipients
that were initiated on antipsychotic therapy in July 2006. ODB
recipients were followed from their ﬁrst claim for the speciﬁc
target drug to their last claim in a 12-month period. Rates of
retention were determined throughout and up until 12 months.
Descriptive analyses were performed. Retention rates were
reported for depot (long-acting injectable) risperidone; oral atypi-
cal antipsychotics including olanzapine, risperidone, and quetiap-
ine; orally disintegrating tablet formulations of risperidone and
olanzapine; oral typical antipsychotics (pooled); and depot typical
antipsychotics (pooled). RESULTS: From July 2006–June 2007,
12-month retention rates were lowest with oral typical (29% of
recipients), depot typical antipsychotics (30%), and risperidone
orally disintegrating formulations (30%). Retention rates for oral
atypical antipsychotics were 41% for olanzapine, 46% for risperi-
done and 50% for quetiapine. Retention on risperidone long-
acting injectable were the highest with 73% of recipients retained
over 12-months. CONCLUSION: Retention rates were lowest
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